
    
      Pre-inclusion stage: Case history, clinical examination, laboratory study, inclusion criteria
      checking.

      Inclusion stage: Inclusion and exclusion criteria checking, clinical examination, disease
      follow-up, written inform consent.

      Ambulatory hospitalisation, laboratory study.

      Treatment and follow-up of the patients.

      Clobetasol propionate cream application and leflunomide introduction.

      After inclusion, the treatment will begin with 40 g topical corticosteroid per day and 20 mg
      leflunomide per day.

      Topical corticosteroids will be progressively decreased during 5 months and stopped.

      Follow-up: monthly during one year in the department of dermatology, university hospital
      (clinical examination, laboratory study).
    
  